Knockdown of MSI1 inhibits the proliferation of human oral squamous cell carcinoma by inactivating STAT3 signaling

Wang,Chen‑Fei; Zhang,Hong‑Chuang; Feng,Xin‑Mei; Song,Xiao‑Meng; Wu,Yu‑Nong

doi:10.3892/ijmm.2019.4181

Knockdown of MSI1 inhibits the proliferation of human oral squamous cell carcinoma by inactivating STAT3 signaling

Authors:
- Chen‑Fei Wang
- Hong‑Chuang Zhang
- Xin‑Mei Feng
- Xiao‑Meng Song
- Yu‑Nong Wu
View Affiliations

Affiliations: Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China, Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 216000, P.R. China
Published online on: May 6, 2019 https://doi.org/10.3892/ijmm.2019.4181
Pages: 115-124
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Musashi RNA‑binding protein 1 (MSI1) is highly expressed in several types of cancer; however, its role in oral squamous cell carcinoma (OSCC) remains unknown. The purpose of this study was to investigate the probable mechanism underlying the involvement of MSI1 in OSCC. The results demonstrated that MSI1 was upregulated in OSCC tissues, but not in adjacent healthy tissues. MSI1 silencing resulted in decreased cell proliferative, invasive and migrative capacity. In addition, MSI1 silencing led to cell cycle arrest at the S phase, downregulation of c‑Myc and cyclin D1, and upregulation of p21 and p27 levels. Additional studies demonstrated that MSI1 suppression inhibited the activation of signal transducer and activator of transcription 3 (STAT3) signaling. Accordingly, the findings of the present study suggested that MSI1 silencing can suppress OSCC cell proliferation and progression, in part by inhibiting the activation of the c‑Myc/STAT3 pathway.

View Figures

View References

1	Brocklehurst PR, Baker SR and Speight PM: Oral cancer screening: What have we learnt and what is there still to achieve? Future Oncol. 6:299–304. 2010. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
3	Kessler P, Grabenbauer G, Leher A, Bloch-Birkholz A, Vairaktaris E and Neukam FW: Neoadjuvant and adjuvant therapy in patients with oral squamous cell carcinoma long-term survival in a prospective, non-randomized study. Br J Oral Maxillofac Surg. 46:1–5. 2008. View Article : Google Scholar
4	Gupta S, Kong W, Peng Y, Miao Q and Mackillop WJ: Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. Int J Cancer. 125:2159–2165. 2009. View Article : Google Scholar : PubMed/NCBI
5	Kapoor A and Kumar S: Cancer stem cell: A rogue responsible for tumor development and metastasis. Indian J Cancer. 51:282–289. 2014. View Article : Google Scholar : PubMed/NCBI
6	Wang Y, Jiang CQ and Fan LF: Correlation of Musashi-1, Lgr5, and pEGFR expressions in human small intestinal adenocarcinomas. Tumour Biol. 36:6075–6082. 2015. View Article : Google Scholar : PubMed/NCBI
7	Liu XF, Yang WT, Xu R, Liu JT and Zheng PS: Cervical cancer cells with positive Sox2 expression exhibit the properties of cancer stem cells. PLoS One. 9:e870922014. View Article : Google Scholar : PubMed/NCBI
8	Wu XS, Xi HQ and Chen L: Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World J Surg Oncol. 10:2442012. View Article : Google Scholar : PubMed/NCBI
9	Chen HY, Lin LT, Wang ML, Tsai KL, Huang PI, Yang YP, Lee YY, Chen YW, Lo WL, Lan YT, et al: Musashi-1 promotes chemoresistant granule formation by PKR/eIF2α signalling cascade in refractory glioblastoma. Biochim Biophys Acta Mol Basis Di. 1864:1850–1861. 2018. View Article : Google Scholar
10	Gong P, Wang Y, Gao Y, Gao M, Liu L, Qu P, Jin X and Gao Q: Msi1 promotes tumor progression by epithelial-to-mesenchymal transition in cervical cancer. Hum Pathol. 65:53–61. 2017. View Article : Google Scholar : PubMed/NCBI
11	Guan A, Wang H, Li X, Xie H, Wang R, Zhu Y and Li R: MiR-330-3p inhibits gastric cancer progression through targeting MSI1. Am J Transl Res. 8:4802–4811. 2016.PubMed/NCBI
12	Liu L, Qiu F, Chen J, Wu D, Nong Q, Zhou Y and Lu J: Functional polymorphism in the MSI1 gene promoter confers a decreased risk of lung cancer in chinese by reducing MSI1 expression. Curr Genomics. 19:375–383. 2018. View Article : Google Scholar : PubMed/NCBI
13	Lang Y, Kong X, He C, Wang F, Liu B, Zhang S, Ning J, Zhu K and Xu S: Musashi1 promotes non-small cell lung carcinoma malignancy and chemoresistance via activating the Akt signaling pathway. Cell Physiol Biochem. 44:455–466. 2017. View Article : Google Scholar : PubMed/NCBI
14	Qin G, Lian J, Yue D, Chen X, Nan S, Qi Y, Li B, Cui G, Li X, Zhao S and Zhang Y: Musashi1, a potential prognostic marker in esophageal squamous cell carcinoma. Oncol Rep. 38:1724–1732. 2017. View Article : Google Scholar : PubMed/NCBI
15	Dahlrot RH: The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dan Med J. 61:B49442014.PubMed/NCBI
16	Moghbeli M, Forghanifard MM, Sadrizadeh A, Mozaffari HM, Golmakani E and Abbaszadegan MR: Role of Msi1 and MAML1 in regulation of notch signaling pathway in patients with esophageal squamous cell carcinoma. J Gastrointest Cancer. 46:365–369. 2015. View Article : Google Scholar : PubMed/NCBI
17	Pastò A, Serafin V, Pilotto G, Lago C, Bellio C, Trusolino L, Bertotti A, Hoey T, Plateroti M, Esposito G, et al: NOTCH3 signaling regulates MUSASHI-1 expression in metastatic colorectal cancer cells. Cancer Res. 74:2106–2118. 2014. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
19	Niu J, Zhao X, Liu Q and Yang J: Knockdown of MSI1 inhibited the cell proliferation of human osteosarcoma cells by targeting p21 and p27. Oncol Lett. 14:5271–5278. 2017.PubMed/NCBI
20	Jadhav S, Ajay AK, Trivedi P, Seematti J, Pellegrini K, Craciun F and Vaidya VS: RNA-binding protein Musashi Homologue 1 regulates kidney fibrosis by translational inhibition of p21 and Numb mRNA. J Biol Chem. 291:14085–14094. 2016. View Article : Google Scholar : PubMed/NCBI
21	Abdelmohsen K, Srikantan S, Kuwano Y and Gorospe M: miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. Proc Natl Acad Sci USA. 105:20297–20302. 2008. View Article : Google Scholar : PubMed/NCBI
22	Busà R, Paronetto MP, Farini D, Pierantozzi E, Botti F, Angelini DF, Attisani F, Vespasiani G and Sette C: The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene. 26:4372–4382. 2007. View Article : Google Scholar : PubMed/NCBI
23	Sutherland LC, Rintala-Maki ND, White RD and Morin CD: RNA binding motif (RBM) proteins: A novel family of apoptosis modulators? J Cell Biochem. 94:5–24. 2005. View Article : Google Scholar
24	Shi C and Zhang Z: miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma. Tumour Biol. 37:5437–5443. 2016. View Article : Google Scholar
25	Akasaka Y, Saikawa Y, Fujita K, Kubota T, Ishikawa Y, Fujimoto A, Ishii T, Okano H and Kitajima M: Expression of a candidate marker for progenitor cells, Musashi-1, in the prolif-erative regions of human antrum and its decreased expression in intestinal metaplasia. Histopathology. 47:348–356. 2005. View Article : Google Scholar : PubMed/NCBI
26	Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J and Dalla-Favera R: Non-transcriptional control of DNA replication by c-Myc. Nature. 448:445–451. 2007. View Article : Google Scholar : PubMed/NCBI
27	Wang Y, Cheng J, Xie D, Ding X, Hou H, Chen X, Er P, Zhang F, Zhao L, Yuan Z, et al: NS1-binding protein radiosensitizes esophageal squamous cell carcinoma by transcriptionally suppressing c-Myc. Cancer Commun (Lond). 38:332018. View Article : Google Scholar
28	Mesquita FP, Pinto LC, Soares BM, de Sousa Portilho AJ, da Silva EL, de Farias Ramos IN, Khayat AS, Moreira-Nunes CA, Bezerra MM, de Lucas Chazin E, et al: Small benzothiazole molecule induces apoptosis and prevents metastasis through DNA interaction and c-MYC gene supression in diffuse-type gastric adenocarcinoma cell line. Chem Biol Interact. 294:118–127. 2018. View Article : Google Scholar : PubMed/NCBI
29	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
30	Redell MS and Tweardy DJ: Targeting transcription factors for cancer therapy. Curr Pharm Des. 11:2873–2887. 2005. View Article : Google Scholar : PubMed/NCBI
31	Deepak Roshan VG, Sinto MS, Thomas S and Kannan S: Cyclin D1 overexpression associated with activation of STAT3 in oral carcinoma patients from South India. J Cancer Res Ther. 14:403–408. 2018.PubMed/NCBI
32	Gkouveris I, Nikitakis N, Avgoustidis D, Karanikou M, Rassidakis G and Sklavounou A: ERK1/2, JNK and STAT3 activation and correlation with tumor differentiation in oral SCC. Histol Histopathol. 32:1065–1076. 2017.PubMed/NCBI
33	Li R, You S, Hu Z, Chen ZG, Sica GL, Khuri FR, Curran WJ, Shin DM and Deng X: Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer. PLoS One. 8:e746702013. View Article : Google Scholar : PubMed/NCBI
34	Sun S and Zhang Z: Patient-derived xenograft platform of OSCC: A renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization. Front Med. 10:104–110. 2016. View Article : Google Scholar : PubMed/NCBI